27 July 2022: Jess Rabourn – RWW: Expanded Access Programs (EAPs) as a source of clinical and nonclinical data

27 July 2022: Conversation with Jess Rabourn, CFA, CEO of WideTrial and Executive Producer of the Expanded Access Summit – We discussed the primary objective of any EAP to provide pre-approval treatment options in situations of unmet medical need ... and a critical secondary objective to generate ongoing RWD from a larger and more representative set of patients within the targeted indication.